Safety and Efficacy Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for GVHD Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT | Synapse
March 3, 2026
Safety and Efficacy Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for GVHD Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Key Points
Patients experienced fewer GVHD complications with ruxolitinib treatment, supporting its efficacy.
The trial observed a 25% reduction in severe GVHD cases at the 6-month mark, indicating a positive outcome.
Phase II trial involved older adults undergoing reduced intensity conditioning for allogeneic HCT.
Findings highlight the importance of tailored treatment approaches for older patients undergoing transplant.